• SENSEX
    NIFTY 50

Cashing in on DNA: race on to unlock value in genetic data

Updated : August 03, 2018 15:29:29 IST

GlaxoSmithKline's decision to invest $300 million in 23andMe and forge an exclusive drug development deal with the Silicon Valley consumer genetics company crystallises the value locked up in genetic code.
The tie-up is the biggest yet involving home DNA testing, a market dominated by 23andMe and Ancestry.com, which charge under $100 for a saliva-based test, but can also gain voluntary consent from customers for their data to be used by third parties.
Cashing in on DNA: race on to unlock value in genetic data
Published : August 03, 2018 03:29 PM IST

You May Also Like

Live TV

recommended for you

Advertisement